Summary The distribution of Gp 170, a multidrug resistance (MDR) associated glycoprotein, also called P-glycoprotein (P-gp), was examined by immunohistochemistry, using C219 and MRK16 monoclonal antibodies. Sixty-five tumour tissues were studied which included 40 non-lymphoid tumours, 15 chemoresistant non-Hodgkin's lymphomas and 10 Hodgkin's disease. The study was performed on both cryostat and special fixation processed and paraplast embedded (ModAMeX) sections. The latter method preserves fixationsensitive antigens such as P-gp and allows a more precise morphological identification of neoplastic and non-neoplastic cell populations in contrast to cryostat sections. Immunohistochemical expression of P-gp was expected and confirmed in many non-lymphoid tumours, but stromal macrophages and endothelial cells were also frequently stained in these cases. In non-Hodgkin's lymphomas, cells that were stained with both C219 and MRK16 monoclonal antibodies on cryostat sections were identified as macrophages and endothelial cells and not neoplastic lymphoid cells, by the ModAMeX technique. These findings suggest that the quantitative assessment of MDR RNA by Northern blotting performed on fresh homogenates overestimates the MDR content of neoplastic cells in a number of lymphoid and non-lymphoid tumours. In addition, the mechanism of chemoresistance in non-Hodgkin's lymphomas is less likely to be associated with P-gp expression.
. P-gp expresion has been evaluated in many tumour samples, either by using quantitation of MDR 1 RNA by hybridisation probes (Fojo et al., 1987a (Fojo et al., , 1987b Goldstein et al., 1989; Moscow et al., 1989) or by the measurement of P-gp over expression by immunoblot using monoclonal antibodies (MoAb) (Bell et al., 1985; Gerlach et al., 1987) . P-gp expression has been found to be elevated in untreated intrinsically drug-resistant tumours, such as colon or renal carcinomas and in some recurrent but originally chemosensitive cancers that include non-Hodgkin's lymphomas (Goldstein et al., 1989; Moscow et al., 1989) .
However, the cellular heterogeneity of P-gp expression as recently identified in experimental models (Shen et al., 1988) (Marie et al., 1989) . Immunohistochemistry offers the advantages of processing routine specimens and is generally considered to be a reliable, sensitive and rapid method for characterising glycoproteins in the cell membranes of tumour cells (Delsol et al., 1989) . Few immunohistochemical studies have yet emphasised the P-gp expression in human tumour biopsy specimens (Salmon et al., 1989; Dalton et al., 1989; Sugawara et al., 1989) . Moreover, these studies have usually been performed with cryostat preparations. In our experience, the precise morphological identification of immunostained cells can be difficult, especially in lymphoid tumours. Several MoAb directed against P-gp have been generated Hamada & Tsuruo, 1986; Scheper et al., 1988) . Among these, MRK16 and C219 MoAb were the most extensively used (Thiebaut et al., 1987; Sugawara et al., 1988; Thiebaut et al., 1989) . We investigated the reactivities of both C219 and MRK16 MoAb in 65 tumour specimens by using both cryostat and paraplast-embedded preparations. The latter technique combines excellent morphology with preservation of most glycoprotein surface antigens (Delsol et al., 1989 (Table I) . The clinical outcome (chemotherapy sensitivity) in these cases was not determined. Ten biopsies of Hodgkin's disease were studied (Table II) . The first eight patients were in complete remission after 3 to 12 ABVD or MOPP cycles whereas 2 patients were in progressive disease. Fifteen cases of non-Hodgkin's lymphomas were enrolled in this study (Table III) . The patients were selected for their chemoresistance to drug regimens which included both adriamycin and vincristine, known to induce P-gp expression. The Table I .
Non-tumour tissues
Adrenal, kidney and liver tissue specimens, freshly obtained from necropsies, were investigated for comparison of known P-gp expression. P-gp expression has been reported to occur on normal adrenal cortical and medullary cells, apical portion of proximal tubular cells of the kidney, and canalicular surface of hepatocytes (Thiebaut et al., 1987) .
Four cases of benign lymph nodes (3 sarcoidosis and 1 reactive lymphadenitis) and a normal spleen from a case of incidental splenectomy were included in the study.
Cell lines
Parental Chinese hamster ovary (CHO) cell line (Aux BI) and the MDR CHRC5 subline , kindly provided by Dr R.M. Baker (RPMI, Buffalo, NY), as well as the parental human KB-3-1 and the adriamycin resistant sublines KB-ADRR_5A and KB-Al (Pastan & Gottesman, 1987) , a generous gift of Dr M. Gottesman (NCI. Bethesda, MD), were used as negative and positive controls.
Monoclonal antibodies
Two MoAb, C219 (Centocor, Malvern) directed against an internal epitope of P-gp and MRK16, which reacts with the external region of the molecule (Hamada et al., 1986) Immunostaining procedure A method for cryostat sections has been described previously (Laurent et al., 1986) . The ModAMeX preparations were warmed to 54°C for 2 minutes before deparaffinisation in xylene for 10 minutes. Sections were then immersed in acetone for 4 minutes, in either Tris-buffered saline (TBS) plus acetone or phosphate buffered saline (PBS) plus acetone for 2 minutes followed by immersion in TBS or PBS for 4 minutes and finally in TBS or PBS plus bovine albumin (1%) for 4 minutes. Both cryostat and ModAMeX sections were stained by the APAAP method (Cordell et al., 1984) . MRK16 and C219 MoAb were used at 4 ;tg ml-' final concentrations. All sections were read by one of us (GD) in batches. Even though no quantitation could be applied to the assessment of staining reactivities, the intensity of the reaction product could be semi-objectively classified as weak, moderate or strong which is the notation that has been used in the presentation of results.
Cell lines CHO and KB cell lines were suspended in culture medium and centrifuged (14 g for 5 minutes) with cytospin 2 (Shandon Inc, Pittsburgh, PA). After fixation with undiluted acetone and chloroform for 15 minutes, the cell lines were processed in the same manner as tissues for cryostat sections as well as by immunoperoxidase (Laurent et al., 1986) and APAAP techniques (Cordell et al., 1984) .
Results
The feasibility of immunohistochemical assessment of the reactivities of MoAb against P-gp was first confirmed with the cell lines. The parental cell lines, CHO Aux Bl and KB-3-1 were negative for both C219 and MRK16 MoAb whereas strong positive reactions were obtained with resistant cell lines, CHO MDR CHRC5 as well as KB-ADRR-5A and KB-Al (adriamycin-resistant) (data not shown).
Positive staining, denoting P-gp expression by neoplastic cells of non-lymphoid tumours, was obtained in 12 out of 40 cases (30%), namely, in renal-cell carcinoma, liver-cell car-cinoma, ovarian cacinoma, astrocytoma, Wilm's tumour, cutaneous localisation of an acute myelomonocytic leukaemia and a breast fibroadenoma (Table I ). In the P-gp expressing tumours, malignant cells were diffusely stained with variable, but generally moderate intensity. The pattern of reactivities of neoplastic cells bore no relation to the type of the neoplasm. We were surprised to find exclusive positivity on macrophages, with the two anti-P-gp antibodies, in 13 out of 40 cases. In these cases, where P-gp expression was solely encountered on macrophages, the neoplastic cells were completely negative. The intensities of the reaction product on the macrophages varied between tumour types but were comparable for a given tumour for the two antibodies. In two instances (liver cell carcinoma and astrocytoma), P-gp expression was found on both neoplastic cells and macrophages (Table I) . P-gp was expressed exclusively by some endothelial cells only in one instance (leiomyosarcoma) and simultaneously with macrophages in one other case (astrocytoma).
In ten cases of Hodgkin's disease (8 chemosensitive and 2 chemoresistant), Reed-Sternberg cells were unstained in all cases while macrophages and endothelial cells were reactive with both C219 and MRK16 MoAb in five cases. The number of cases in each histological type are too few to draw meaningful correlation with histopathological subtypes.
In non-Hodgkin's lymphomas, a clear immunostaining, but with a variable proportion of cells in each case, was obtained with both C219 and MRK16 MoAb in 13 out of 15 cases (86%) on cryostat sections. Positive cells were either in small clusters or scattered throughout microscopic fields. The intensity of the immunostaining varied but was often strong. Accurate cytological identification of stained cells remained uncertain on cryostat sections. However, these immunoreactive cells were positively identified as macrophages in ModAMeX prepared sections (Figure 1 ). In addition to the characteristic morphology, some immunostained cells showed tingible bodies in their cytoplasm. The neoplastic lymphoid cells were clearly negative in all cases of non-Hodgkin's lymphoma (Table III) . The reactivity of macrophages by anti-P-gp antibodies was further confirmed by simultaneous staining of serial sections in three cases with CD68 antibodies (Figure 2 ). It needs to be noted though, that the proportion of macrophages stained with the CD68 was greater than those stained by the two anti-P-gp MoAb.
Five specimens of non-malignant lymphoid tissue (3) sarcoidosis, 1 non-specific reactive lymphadenitis, and I normal spleen) were examined. Normal and reactive lymphocytes were negative for P-gp expression both in lymph nodes and in the spleen. Variable and inconsistent staining was observed on endothelial cells of capillaries in lymph node and spleen with the two antibodies. In lymph node, but not in the spleen, numerous epitheloid macrophages, mainly in aggre- gates, were strongly stained with both C219 and MRK16 MoAb similar to the findings in tumour specimens. In one case of sarcoidosis and one case of lymphadenitis, CD68 antibodies were used on serial sections to confirm the macrophage nature of the P-gp expressing cells. Discussion C219 and MRK16 have been used previously for characterisation of P-gp expression in normal tissues on cryostat sections (Thiebaut et al., 1987; Sugawara et al., 1988; Thiebaut et al., 1989) . Localisation of P-gp has been found on biliary canalicular front of hepatocytes, apical portions of proximal tubular cells of the kidney and diffusely in adrenal cortical and medullary cells with the two antibodies (Thiebaut et al., 1987; Thiebaut et al., 1989) . On both cryostat sections and ModAMeX processed sections we found P-gp expression in normal tissues similar to that reported by these authors. P-gp expression by neoplastic cells in cases of renal-cell carcinoma, liver-cell carcinoma and ovarian carcinoma was expected from the reported Northern blot studies (Fojo et al., 1987b; Goldstein, et al., 1989; Moscow et al., 1989) . In addition P-gp expression could be identified on resistant cell lines compared to its absence on parental cell lines. These observations confirmed the reliability of immunohistochemical methods for studying P-gp expression in human cancers. Moreover, the strong reactivities observed in paraplast preparations showed that the ModAMeX technique, which was essentially developed for optimal preservation of leucocyte differentiation antigens, is equally feasible for the immunodetection of P-gp.
Patients with non-Hodgkin's lymphoma were selected on the basis of their resistance to drugs normally involved in the MDR phenotype. We were surprised to find the lack of P-gp expression by lymphoma cells in all cases. Our results are in conflict with those reported by Salmon et al. (1989) and Dalton et al. (1989) , who found at least 50% positive cases (3/6 and 1/1 respectively) with a biotin-avidin conjugated immunoperoxidase method using JSB-l and C219 MoAb. Such a discrepancy cannot be explained either by the selection of patients, or by the immunostaining methods, since, in our experience, the APAAP technique used in our study is as sensitive as the biotin-avidin procedure. It is possible that the heterogeneity of the results is due to the small size of the patient populations in previous studies. In a recent report, Sugawara et al. (1989) did not find significant staining of lymphoma cells by MRKl6 MoAb using flow cytometry.
Furthermore, Northern blot studies have shown that the incidence of MDR in lymphoma patients is rather low, accounting for only about 30% of the patients with moderate or low MDR1 RNA levels (Goldstein et al., 1989; Moscow et al., 1989) . The latter findings are in line with our study and suggest that drug resistance to CHOP or CHOP-derived regimens in lymphomas could be mediated by mechanisms other than P-gp over expression. P-gp expression in Hodgkin's disease has not been previously reported. In our study, Reed-Sternberg cells did not express P-gp. However, these patients had not been selected on the basis of their chemotherapeutic unresponsiveness, since 8 of 10 patients achieved complete remission after first line MOPP/ABVD treatment. Further studies on MOPP/ABVD resistant patients are needed to assess the possible role of MDR in refractory Hodgkin's disease.
Interestingly, we found positivity of numerous stromal cells in some non-lymphoid and lymphoid tumours (Figure 1 ) as well as in non-tumoural inflammatory processes. In these cases, macrophages, mainly in aggregates, were positive with both C219 and MRK16 MoAb. The reactivity appears specific because the two antibodies recognise two different membrane epitopes. The findings need to be strengthened further by in situ hybridisation with a specific MDR-1 probe (currently in progress). P-gp was not expressed by macrophages in all tumours, neither did all macrophages in the same tumour express P-gp. It is possible, therefore, that the positivity is due to the expression of P-gp by a subset of macrophages. In this context, cellular activation signals involved in antitumour host responses or inflammatory processes may trigger cells of the monocyte/macrophage system to induce P-gp expression. The mechanism of P-gp expression by macrophages remains to be elucidated but our findings suggest that these cells are responsible in some instances for an overestimation of the MDR content of tumour cells with Northern blot or immunoblot techniques performed on fresh tissues homogenates.
Finally, this study confirms that immunohistochemistry represents a useful tool for studying P-gp expression in human cancers, especially if the technique used allows a precise morphological assessment of antigen distribution and bypasses the interpretative difficulties of cryostat sections. However, immunomorphology does not allow exact quantification of P-gp content. Therefore, it may be advisable to combine immunohistochemical and molecular biology techniques for exploring any putative correlation between MDR expression and the clinical outcome.
